Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Plaque Psoriasis
Interventions: Roflumilast; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Conditions: Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin, Acute Lymphoblastic Leukemia (ALL), Myeloproliferative Syndrome, Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
Interventions: CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon), Myeloablative Conditioning Regimen; Biological · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 73 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cancer
Interventions: Harbinger Health Test; Diagnostic Test
Lead sponsor: Harbinger Health; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 8,038 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 128
States / cities: Daphne, Alabama • Anchorage, Alaska • Prescott Valley, Arizona + 93 more

Conditions: Femoral Fractures, Tibial Fractures
Interventions: Retrograde Femoral Nail Advanced, Tibial Nail Advanced; Device
Lead sponsor: DePuy Synthes Products, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Columbia, Missouri + 5 more

Conditions: Age-Related Macular Degeneration
Interventions: DE-120; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Bakersfield, California • Beverly Hills, California • Dallas, Texas

Conditions: Head and Neck Neoplasms
Interventions: M4N; Drug
Lead sponsor: Erimos Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: Breast Ultrasound Imaging With Investigational AI Software; Device
Lead sponsor: AURA Health Technologies; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: No intervention; Other
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel, Radiation Therapy; Drug · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Kidney Cancer
Interventions: Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250); Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Prolapse Genital
Interventions: MRI; Diagnostic Test
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sleep, Sleep Apnea Syndromes, Sleep Disordered Breathing
Interventions: Observational follow-up study of adenotonsillectomy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 3 Years to 12 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Neoplasms
Interventions: GSK6097608, Dostarlimab, Cobolimab, Belrestotug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Metastatic Cancer, Renal Cancer
Interventions: Atezolizumab, Bevacizumab, Entinostat; Drug
Lead sponsor: Roberto Pili; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Low Back Pain
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Marburg Hemorrhagic Fever
Interventions: AVI-7288, Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Abdominal Pain, Pelvic Pain
Interventions: Pelvic US; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Patient Satisfaction
Interventions: SMS; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV Infections
Interventions: Romidepsin, Placebo for Romidepsin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Neoplasms
Interventions: Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more

Conditions: Bladder Dysfunction, Neurogenic Bladder
Interventions: It's is a cohort; Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions: liver transplant; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBA-7371, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Eye Diseases
Interventions: WiSLO, Volk Pictor Plus™; Device
Lead sponsor: Duke University; Other
Eligibility: 30 Days and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Development and Validation of Harbinger Health Test for Early Cancer Detection

Depuy Synthes Lower Extremity Shaft Nail Registry

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

Prospective Ultrasound Data Collection Study for AI-Based Detection of Breast Biopsy Markers

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse

Identification of Sleep-Disordered Breathing in Children

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

A Prospective Cohort Study of MR Abnormalities and Back Pain Risk

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

Transvaginal Pelvic Ultrasound in the ED

Short Message Service Based Patient Education in Spine Patients

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Deep Brain Stimulation in Patients With LUTS

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging